TP53 and neoplasm: Apart from known ccRCC oncogenic alterations, one tumour harboured NF2 and CDKN2A mutations exclusively in its mesenchymal component, and 2 tumours had TP53 mutations that were present exclusively in the mesenchymal component of these tumours.